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Abstract
© 2016 American Association for Cancer Research.Recent findings suggest that the inhibition of
Aurora A (AURKA) kinase may offer a novel treatment strategy against metastatic cancers. In
the current study, we determined the effects of AURKA inhibition by the small molecule inhibitor
MLN8237  both  as  a  monotherapy  and  in  combination  with  the  microtubuletargeting  drug
eribulin on different stages of metastasis in triplenegative breast cancer (TNBC) and defined the
potential mechanism of its action. MLN8237 as a single agent and in combination with eribulin
affected  multiple  steps  in  the  metastatic  process,  including  migration,  attachment,  and
proliferation  in  distant  organs,  resulting  in  suppression  of  metastatic  colonization  and
recurrence of cancer. Eribulin application induces accumulation of active AURKA in TNBC cells,
providing foundation for the combination therapy. Mechanistically, AURKA inhibition induces
cytotoxic autophagy via activation of the LC3B/p62 axis and inhibition of pAKT, leading to
eradication of metastases, but has no effect on growth of mammary tumor. Combination of
MLN8237 with eribulin leads to a synergistic increase in apoptosis in mammary tumors, as well
as cytotoxic autophagy in metastases. These preclinical data provide a new understanding of
the mechanisms by which MLN8237 mediates its antimetastatic effects and advocates for its
combination with eribulin in future clinical trials for metastatic breast cancer and early-stage
solid tumors.
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